Urology Endoscopes Market to Exceed $1 Billion in Six Years

The global urology endoscopes market is set to rise from around $813 million in 2016 to $1.4 billion by 2023, representing a relatively strong compound annual growth rate (CAGR) of 8.4 percent, according to research and consulting firm GlobalData.
 
The company’s latest report on urology endoscopes, which include cystoscopes, resectoscopes, and ureteroscopes and covers 39 countries, states that these scopes are used for diagnosing and treating disorders related to the upper and lower urinary tract, including the management of stones in the kidney, ureter, and bladder, as well as urothelial tumors.
 
“One of the primary growth factors affecting the market is the technological advancement in optical imaging and product performance, helping urologists better diagnose and treat underlying causes of disease,” explained Vinie Varkey, MSc, healthcare analyst for GlobalData. “For example, white light cystoscopy is the standard optical mode used to evaluate bladder urothelium. However, there are limitations associated with this technology because its visual determination of low grade and high grade cancer is unreliable. Recent optical imaging developments have helped to overcome this limitation, however, such as narrow-band imaging, which offers a high-resolution, wide-field view with enhanced visualization of mucosal and submucosal vasculature without the need to introduce a contrast dye.”
 
North America currently dominates the urology endoscopes market, and is expected grow at a CAGR of 10.7 percent, followed by the Asia-Pacific (APAC) region with a CAGR of 7 percent, and Europe with a CAGR of 5.1 percent. Regional adoption of urology endoscopes tends to depend on factors such as reimbursement, infrastructure capabilities, and the financial resources of healthcare settings in individual markets.
 
“In North America, the primary driver of market growth is the increase in the number of urologic procedures caused by an increase in the prevalence and incidence of diseases affecting the urinary tract, particularly urolithiasis. According to GlobalData, the U.S. dominates the region with an estimated market value of $273 million in 2016, followed by Canada and Mexico,” Varkey said.
 
“The APAC region, meanwhile, has the potential to expand the overall market significantly, as there are increasing efforts from urologists to learn about new techniques and to adopt best practices in the management of urological diseases,” Varkay concluded.
 
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.

GlobalData plc formed in early 2016 following the consolidation of a series of well-established data and insights solution providers including Canadean, Kable, Current Analysis, Conlumino, Pyramid Research, Verdict, ERC, and PharmSource.